[{"address1": "900 West Platt St", "address2": "Suite 200", "city": "Tampa", "state": "FL", "zip": "33606-2173", "country": "United States", "phone": "813-864-2562", "website": "https://inhibitortx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. It has license agreement with Johns Hopkins University. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida. Inhibitor Therapeutics, Inc operates as a subsidiary of Mayne Pharma Ventures Pty Ltd.", "fullTimeEmployees": 3, "companyOfficers": [{"maxAge": 1, "name": "Dr. Francis E. O'Donnell Jr., M.D.", "age": 73, "title": "Founder, Executive Chairman & CEO", "yearBorn": 1950, "fiscalYear": 2023, "totalPay": 1089337, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. James A. McNulty CPA", "age": 73, "title": "Interim CFO, Treasurer & Secretary", "yearBorn": 1950, "fiscalYear": 2023, "totalPay": 337958, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "open": 0.06, "dayLow": 0.06, "dayHigh": 0.06, "regularMarketOpen": 0.06, "regularMarketDayLow": 0.06, "regularMarketDayHigh": 0.06, "volume": 100, "regularMarketVolume": 100, "averageVolume": 30635, "averageVolume10days": 20840, "averageDailyVolume10Day": 20840, "bid": 0.06, "ask": 0.0785, "marketCap": 11373384, "fiftyTwoWeekLow": 0.034, "fiftyTwoWeekHigh": 0.138, "fiftyDayAverage": 0.07688, "twoHundredDayAverage": 0.07911, "trailingAnnualDividendYield": "NaN", "currency": "USD", "enterpriseValue": 4185129, "floatShares": 78155621, "sharesOutstanding": 172324000, "sharesShort": 19880, "sharesShortPriorMonth": 40, "sharesShortPreviousMonthDate": 1260835200, "dateShortInterest": 1263513600, "sharesPercentSharesOut": 0.0023, "heldPercentInsiders": 0.58479, "shortRatio": 0.08, "shortPercentOfFloat": 0.0036000002, "impliedSharesOutstanding": 172324000, "bookValue": 0.02, "priceToBook": 3.3, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -3084616, "trailingEps": -0.02, "52WeekChange": -0.28440368, "SandP52WeekChange": 0.2729931, "exchange": "OQB", "quoteType": "EQUITY", "symbol": "INTI", "underlyingSymbol": "INTI", "shortName": "Inhibitor Therapeutics Inc.", "longName": "Inhibitor Therapeutics, Inc.", "firstTradeDateEpochUtc": 1379079000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "fe7e17dd-fe3d-3d39-983f-61295e0babc4", "messageBoardId": "finmb_369680", "gmtOffSetMilliseconds": -18000000, "currentPrice": 0.066, "recommendationKey": "none", "totalCash": 6378304, "totalCashPerShare": 0.037, "quickRatio": 143.143, "currentRatio": 144.784, "returnOnAssets": -0.26826, "returnOnEquity": -0.6258, "freeCashflow": -2255180, "operatingCashflow": -3159314, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-12-28"}]